News Releases


 

Jan 3, 2018

Insmed Announces Additional Data from ALIS (Amikacin Liposome Inhalation Suspension) Phase 3 Clinical Program for Adult Patients with Treatment Refractory NTM Lung Disease Caused by MAC and Reports Progress with Commercial Preparations

Nov 28, 2017

Insmed to Present at the Nasdaq 37th Annual Investor Conference

Nov 22, 2017

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nov 8, 2017

Insmed to Present at Two November Conferences

Nov 2, 2017

Insmed Reports Third Quarter 2017 Financial Results and Provides Business Update

Oct 25, 2017

Insmed to Host Third Quarter 2017 Financial Results Conference Call on Thursday, November 2, 2017

Sep 19, 2017

Insmed to Present at Two September Investor Conferences

Sep 11, 2017

Insmed Announces Closing of Public Offering

Sep 6, 2017

Insmed Announces Pricing of Public Offering of Common Stock

Sep 5, 2017

Insmed Announces Proposed Public Offering of Common Stock

1
...
NextLast